Zaloguj się

Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Ujawnienia
  • Podziękowania
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

Here, we present a protocol for co-immunoprecipitation and an on-bead enzymatic activity assay to simultaneously study the contribution of specific protein domains of plasma membrane receptors to both enzyme recruitment and enzyme activity.

Streszczenie

Receptor-associated enzymes are the major mediators of cellular activation. These enzymes are regulated, at least in part, by physical interactions with cytoplasmic tails of the receptors. The interactions often occur through specific protein domains and result in activation of the enzymes. There are several methods to study interactions between proteins. While co-immunoprecipitation is commonly used to study domains that are required for protein-protein interactions, there are no assays that document the contribution of specific domains to activity of the recruited enzymes at the same time. Accordingly, the method described here combines co-immunoprecipitation and an on-bead enzymatic activity assay for simultaneous evaluation of interactions between proteins and associated enzymatic activation. The goal of this protocol is to identify the domains that are critical for physical interactions between a protein and enzyme and the domains that are obligatory for complete activation of the enzyme. The importance of this assay is demonstrated, as certain receptor protein domains contribute to the binding of the enzyme to the cytoplasmic tail of the receptor, while other domains are necessary to regulate the function of the same enzyme.

Wprowadzenie

Catalytic receptors and receptor tyrosine kinases are transmembrane proteins in which binding of an extracellular ligand causes enzymatic activity on the intracellular side1. Some receptors possess both receptor and enzymatic functions, while others recruit specific enzymes such as kinases and phosphatases to their cytoplasmic tails. Recruitment of an enzyme to the receptor's tail and the subsequent catalytic action of this enzyme are two separate processes that are not always regulated by the same protein domains2. Unfortunately, there are no specific tools to assess both the interaction and enzymatic activity simultaneously. The functional co-immunoprecipitation assay described here is a useful method to dissect the recruitment of an enzyme to the tail of a receptor from its activation. This assay utilizes immunoprecipitation of tagged receptors by antibody-coated beads. Subsequently, both an enzymatic activity assay and western blot analysis on beads are performed. The overall goal of this method is to uncover which protein domains are necessary for interactions between receptors and enzymes (assessed by western blot analysis) and which domains are obligatory for complete activation of the enzymes (measured by on-bead enzymatic activity assay). It is significant to develop tools for studying the separate functions of receptor-associated enzymes due to their involvement in the pathogenesis of human diseases. Moreover, further understanding the mechanisms of action of these proteins may help the design of novel therapeutic interventions.

Programmed death-1 (PD-1) is an inhibitory receptor on the surface of T cells and is required for limiting excessive T cell responses. In recent years, anti-PD-1 antibodies have been implicated in the treatment of multiple malignancies1,2. PD-1 ligation restrains numerous T cell functions, including proliferation, adhesion, and secretion of multiple cytokines3,4,5. PD-1 is localized to the immunological synapse, the interface between T cells and antigen-presenting cells6, where it colocalizes with the T cell-receptor (TCR)7. Subsequently, the tyrosine phosphatase SHP2 [Src homology 2 (SH2) domain containing tyrosine phosphatase 2] is recruited to the cytoplasmic tail of PD-1, leading to dephosphorylation of key tyrosine residues within the TCR complex and its associated proximal signaling molecules3,4,5,8,9. The cytoplasmic tail of PD-1 contains two tyrosine motifs, an immunoreceptor tyrosine-based inhibitory motif (ITIM), and an immunoreceptor tyrosine based-switch motif (ITSM)10. Both motifs are phosphorylated upon PD-1 ligation9,10. Mutagenesis studies have revealed a primary role for the ITSM in SHP2 recruitment, as opposed to the ITIM, whose role in PD-1 signaling and function is not clear4.

SHP2 adopts either a closed (folded), inhibited conformation or an open (extended), active conformation11. The contribution of each tail domain of PD-1 to SHP2 binding or activation has not yet been elucidated. To answer this question, we developed an assay that enables parallel testing of the recruitment of SHP2 to the tail of PD-1 and its activity12. We employed co-immunoprecipitation and an on-bead phosphatase activity assay to test both the interaction and enzymatic activity in parallel. Using this assay, we show that the ITSM of PD-1 is sufficient to recruit SHP2 to the tail of PD-1, while the ITIM of PD-1 is needed to fully extend and activate the enzyme.

There are many receptors that have several adjacent domains in their cytoplasmic tails. The functional co-immunoprecipitation assay can uncover the role of specific domains that are necessary for either protein recruitment or enzymatic activation.

Protokół

1. Transfection of Cells

  1. Seed HEK 293T cells into twelve 10 cm plates (5 x 106 cells per plate) the day before transfection (Figure 1). Perform the cell counting using a hemocytometer. For each plate, use 10 mL of DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Incubate the cells at 37 °C in 5% CO2.
  2. Once the cells are 80-90% confluent, transfect 5 HEK 293T plates using a lipid-based transfection reagent with one of the following plasmids: a SHP2-expressing vector, a PD-1-GFP-expressing vector [a wild type (WT) version of PD-1], an ITIM-mutated version (Y223F) of a PD-1-GFP-expressing vector, and an ITSM-mutated version (Y248F) of a PD-1-GFP-expressing vector (Figure 1).
    NOTE: Two plates will be transfected with the WT PD-1-GFP-expressing vector. One additional plate will serve as a non-transfected cells control (Figure 1).
  3. Perform the transfection as per the manufacturer's protocol for adherent cells in 10 cm plates.
    NOTE: In the mutated versions of PD-1, the tyrosine (Y) in each motif was replaced by phenylalanine (F) that cannot be phosphorylated.
  4. Transfect a second identical set of five plates and one additional plate serving as a non-transfected control for the measurement of expressed protein amount [input; also known as whole cell lysate (WCL)] before the immunoprecipitation (Figure 1).
  5. Incubate the transfected cells for 48 h in 37 °C, 5% CO2 in a tissue culture incubator.
    NOTE: To ensure that transfection has successfully occurred, examine the cells for GFP expression using a fluorescent microscope.

2. Promoting Phosphorylation in Transfected Cells

  1. Following incubation, prepare fresh pervanadate by mixing 50 µL of sodium-orthovanadate (from 100 mM stock) with 50 µL of 30% H2O2.
    NOTE: The mixture should change into a yellowish color. Pervanadate is a cell-permeable phosphatase inhibitor that promotes phosphorylation of tyrosine residues13. In this assay, it is used to robustly induce phosphorylation of the tails of PD-1.
  2. To phosphorylate the tagged versions of PD-1, remove the media from the PD-1-GFP-transfected cells and add 10 mL of plain DMEM (without serum or antibiotics) together with 10 µL of pervanadate (step 2.1) to each 10 cm plate (resulting in eight plates expressing different versions of PD-1) (Figure 1). Place the plates at room temperature in the dark for 15 min.
    NOTE: The SHP2-transfected cells (two plates; Figure 1) and the two non-transfected control plates are not treated with pervanadate, since these plates will serve as the source for the active SHP2 enzyme.
  3. Wash the cells with 5 mL of ice-cold 1x PBS. Repeat this step twice.

3. Immunoprecipitation

NOTE: The following steps should be performed on ice or at 4 °C.

  1. Supplement the lysis buffer (50 mM Tris-HCl at pH 7.2, 250 mM NaCl, 0.1% NP-40, 2 mM EDTA, 10% glycerol) with protease inhibitors (dissolve 1 tablet in 10 mL of lysis buffer) and with 1 mM sodium orthovanadate. Add 500 µL of ice-cold lysis buffer to the cells and remove and collect the cells from the plates immediately using a cell scraper.
    NOTE: It is important to add the sodium orthovanadate only to the lysis buffer that will be used for the PD-1-GFP-transfected plates, since the SHP2-transfected plates and non-transfected control plates must retain phosphatase activity.
  2. Transfer the lysates into 1.5 mL cold tubes and rotate them at 0.005 x g, 4 °C for 30 min.
  3. To collect the post nuclei supernatant (PNS) from the lysates, spin down the lysates for 10 min at 10,000 x g at 4 °C and transfer the supernatants into new tubes. Discard the pellet. Store the supernatants of the second set of six plates (Figure 1) on ice for later WCL analysis.
  4. Preparation of the anti-GFP beads for immunoprecipitation of PD-1-GFP from the PD-1-GFP-transfected lysates of the first set (four plates) (Figure 1).
    1. To prevent settling of the beads, gently shake the bottle with the beads before opening. Remove 40 µL of the anti-GFP beads from the slurry per each condition.
    2. Spin at 500 x g for 3 min at 4 °C and remove the supernatant to wash the beads.
      NOTE: It is important to minimize the contact between the pipette plastic tips and agarose beads to prevent loss. It is recommended to cut the edge of a 200 µL tip before transferring the beads to another tube.
    3. Resuspend the beads in 80 µL of lysis buffer (per sample).
  5. Add the washed beads directly to the cell lysate (PNS) from the PD-1-GFP-expressing cells of the first set (four plates) (step 3.3). Rotate at 0.005 x g for 30 min at 4 °C to immunoprecipitate the GFP-tagged proteins.
  6. Wash the beads with 1 mL of cold lysis buffer (without orthovanadate) 3 times. Centrifuge the tube at 2,500 x g for 10 s.
    NOTE: When adding the lysis buffer to the beads, add it directly onto the beads without touching them with the tips. There is no need to pipette up and down during the washes.
  7. Equally divide the lysate of the active SHP2 from the first set (one plate; step 3.3) and add it to three tubes of the washed PD-1-GFP-containing beads (the WT PD-1-GFP and the two different phosphdeficient mutations, Y223F and Y248F). Add one-third of the volume from the lysate of the non-transfected cells to the second tube of the WT PD-1-GFP beads. Discard the remaining two-thirds.
  8. Incubate the beads for 4 h at 4 °C with gentle rotation (0.005 x g).
  9. Wash the beads twice with 1 mL of cold lysis buffer (without pervanadate or orthovanadate), as reported in step 3.6.
  10. Add 80 µL of lysis buffer (without pervanadate or orthovanadate) per sample ensuring that the total volume in each tube is 100 µL (20 µL of beads and 80 µL of lysis buffer). Mix gently and transfer 50 µL from each tube into two fresh 1.5 mL tubes.
    NOTE: Following this step, there will be two tubes filled with a mixture that contains beads and lysis buffer: one tube will be used for testing the co-immunoprecipitated SHP2 by western blotting, and the second will be used for the phosphatase activity assay.

4. Phosphatase Activity Assay

  1. Wash the beads once with phosphatase wash buffer (30 mM Hepes at pH 7.4 and 120 mM NaCl). Remove the supernatant completely.
  2. Add 100 µL of assay buffer (30 mM Hepes at pH 7.4, 120 mM NaCl, 5 mM DTT, 10 mM p-nitrophenylphosphate) to the beads, and incubate at 30 °C for 30 min under gentle agitation. NOTE: Incubation time may vary, but wait until the buffer turns yellow upon dephosphorylation.
  3. To terminate the reaction, add 50 µL of 1 M NaOH when the buffer turns yellow.
  4. Spin down at 2,500 x g for 10 s and transfer 50 µL of the supernatant to two wells (duplicates with 50 µL per well) of half-area in a 96-well plate. Read the absorbance at 405 nm.
  5. Express the results as relative optical density (OD) over the control wild-type version of PD-1-GFP.

5. SHP2 Western Blot Analysis

  1. Spin down the beads and remove the supernatant.
  2. Add 20 µL of 2x Laemmli buffer (see Materials Table) to the beads and boil at 95 °C for 5 min.
  3. Measure the protein concentration of the input controls (second set) using a BCA kit (see Materials Table). Transfer 30 µL of the most diluted sample to a new tube. Dilute the rest of the input controls with lysis buffer to the same concentration as the most diluted sample, and transfer 30 µL from each of them to a new tube.
    NOTE: Following this step, there will be 4 tubes with 30 µL each, at similar protein concentrations, representing the input controls lysates.
  4. Add equal volumes of 2x Laemmli buffer to the lysates and boil at 95 °C for 5 min. Spin down the beads and load the supernatant on 4–20% SDS-PAGE Tris-based gel (see Materials Table) for western blot analysis. In addition, load 50 µL from each sample of the second set.
  5. Continue western blot analysis according to the protocol previously described12.

Wyniki

While the contribution of the ITSM of PD-1 to SHP2 binding is established, the role of the ITIM of PD-1 is less clear. Because SHP2 has two SH2 domains that can bind to two sequential phosphotyrosines on PD-1 (one tyrosine in the ITSM and another in the ITIM), we hypothesized that the ITSM of PD-1 anchors SHP2 to PD-1, while the ITIM of PD-1 facilitates SHP2 activity by stabilizing its open conformational state11,14. To test this,...

Dyskusje

Receptor-enzyme interactions are crucial for intracellular signaling. Many enzymes are recruited to receptors through SH2 domains binding to phosphorylated tyrosines that decorate tails of the same receptors. However, enzymes are often folded into closed inactive conformations, and activation requires a conformational change11 that can be mediated by other domains of the same receptor. The assay described here measures the interactions between receptors and enzymes as well as the activity induced ...

Ujawnienia

The authors have nothing to disclose.

Podziękowania

This project was funded by NIH Grants 1R01AI125640-01 and the Rheumatology Research Foundation.

Materiały

NameCompanyCatalog NumberComments
PBSLonza17-516FPhosphate Buffered Saline
MicrocentrifugeEppendorf5424-R1.5 mL
Trypsin-EDTA (0.25%) Phenol RedGibco25200114
Heat Inactivated FBSDenvilleFB5001-HFetal bovine serum
Penicillin / StreptomycinFisherBP295950
DMEM high glucose without L-glutamineLonzaBE12-614F
SuperFect Transfection ReagentQiagen301305
Anti-SHP2Santa CruzSC-280
Anti–GFP-agaroseMBLD153-8
Anti-GFPRoche118144600
Anti-ActinSanta CruzSC-1616
HEK-293 cellsATCCCRL-1573
OrthovanadateSigmaS6508
H2O2Sigma21676330%
Protease inhibitor cocktailRoche11836170001EDTA-free
Tris-Glycine SDS Sample Buffer (2x)InvitrogenLC2676Modified Laemmli buffer
4-20% Tris-Glycine Mini GelsInvitrogenXP04205BOX15-well
Nitrocellulose membranesGeneral Electric10600004
NaClSigmaS7653Sodium chloride
HEPESGibco15630080N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid
DTTInvitrogenD1532Dithiothreitol
pNPPSigma20-106p-Nitrophenyl Phosphate
NaOHSigmaS8045Sodium hydroxide
BCAFisher23225Bi Cinchoninic Acid assay

Odniesienia

  1. Montor, W. R., Salas, A., Melo, F. H. M. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Molecular Cancer. 17 (1), (2018).
  2. Ngoenkam, J., Schamel, W. W., Pongcharoen, S. Selected signalling proteins recruited to the T-cell receptor-CD3 complex. Immunology. 153 (1), 42-50 (2018).
  3. Azoulay-Alfaguter, I., Strazza, M., Pedoeem, A., Mor, A. The coreceptor programmed death 1 inhibits T-cell adhesion by regulating Rap1. Journal of Allergy and Clinical Immunology. 135 (2), 564-567 (2015).
  4. Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., Riley, J. L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. The Journal of Immunology. 173 (2), 945-954 (2004).
  5. Patsoukis, N., et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Science Signaling. 5 (230), 46 (2012).
  6. Pentcheva-Hoang, T., Chen, L., Pardoll, D. M., Allison, J. P. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proceedings of the National Academy of Sciences of the United States of America. 104 (45), (2007).
  7. Yokosuka, T., et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. The Journal of Experimental Medicine. 209 (6), 1201-1217 (2012).
  8. Hui, E., et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 355 (6332), 1428-1433 (2017).
  9. Sheppard, K. A., et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Letters. 574 (1-3), 37-41 (2004).
  10. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America. 98 (24), 13866-13871 (2001).
  11. Sun, J., et al. Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2. Nature Communications. 4, 2037 (2013).
  12. Peled, M., et al. Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. Proceedings of the National Academy of Sciences of the United States of America. 115 (3), E468-E477 (2018).
  13. Jang, S. H., et al. A protein tyrosine phosphatase inhibitor, pervanadate, inhibits angiotensin II-Induced beta-arrestin cleavage. Molecules and Cells. 28 (1), 25-30 (2009).
  14. Pluskey, S., Wandless, T. J., Walsh, C. T., Shoelson, S. E. Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. The Journal of Biological Chemistry. 270 (7), 2897-2900 (1995).
  15. McAvoy, T., Nairn, A. C. Serine/threonine protein phosphatase assays. Current Protocols in Molecular Biology. , (2010).
  16. Shlapatska, L. M., et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. The Journal of Immunology. 166 (9), 5480-5487 (2001).

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

Co immunoprecipitationReceptor enzyme InteractionCell SignalingProtein DomainsEnzymatic ActivationDMEM293 T CellsTransfectionGFP ExpressionPervanadatePhosphorylationPD 1Lysis BufferProtease InhibitorsSodium OrthovanadateImmunoprecipitation

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Badania

Edukacja

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone